CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading

We recently published These 10 Stocks Surprisingly Lead Gains While Wall Street Naps. CRISPR Therapeutics AG (NASDAQ:CRSP) is one of this week’s top performers.

CRISPR Therapeutics soared by 18.22 percent on Friday to close at $65.13 apiece to hit a new all-time high as investors took path from a recent insider trading that gobbled up shares worth more than $51 million in the company.

In a regulatory filing, CRISPR Therapeutics AG (NASDAQ:CRSP) said its director, George Simeon, snapped up 989,812 shares of the company at a price of $52.03 apiece. The shares were all bought on Wednesday, July 16.

Based on its historical earnings performance, CRISPR Therapeutics AG (NASDAQ:CRSP) is set to release the results of its second quarter earnings performance in the first week of August 2025.

In the first quarter of the year, CRISPR Therapeutics AG (NASDAQ:CRSP) widened its net loss by 17 percent to $136 million from $116 million previously.

Revenues, however, jumped by 71.6 percent to $865 million from $504 million year-on-year.

While we acknowledge the potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.